Профилактика атеросклероза: цели гиполипидемической терапии и реальные возможности розувастатина

1. Шальнова С.А., Деев А.Д., Оганов Р.Г. Факторы, влияющие на смертность от сердечно-сосудистых заболеваний в Российской популяции. Кардиоваск. тер. и проф. 2005; 4 (1): 4–9.
2. Grundy SM, Cleeman JI, Merz CN et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trial for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227–39.
3. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. Eur J Cardiovasc Prevention and Rehabilitation 2007; 4 (Suppl. 2).
4. Российские рекомендации IV пересмотра. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. М., 2009.
5. Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at of vascular disease (PROSPER) randomized controlled trial. Lancet 2002; 360: 1623–30.
6. McKenney JM Pharmacologic Options for aggressive low-density lipоprotein cholesterol lowering: benefits versus risks. Am J Cardiol 2005; 96 (4A): 60E–6E.
7. EUROASPIRE II Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II. Eur Heart J 2001; 22: 554–72.
8. Pearson TA. The undertreatment of LDL-cholesterol: addressing the challenge. Int J Cardiol 2000; 74 (Suppl.): S23–8.
9. Ganse EV, Laforest L, Alemao E et al. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin 2005; 21: 1389–99.
10. Шальнова С.А., Деев А.Д. Уроки ОСКАР – «Эпидемиология и особенности терапии пациентов высокого риска в реальной клинической практике 2005–2006 г.». Кардиоваск. тер. проф. 2007; 6: 47–53.
11. McKenney JM, Jones PH, Adamczyk MA et al. Comparison of efficacy of rosuvastatin verus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003; 19: 689–98.
12. Olsson AG, McTaggart F, Roza A. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 2002; 20: 303–28.
13. White CM. A reviews of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 2002; 42: 963–70.
14. Blasetto JW, Stein EA, Brown WV et al. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. Am J Cardiol 2003; 91 (Suppl.): 3C–10C.
15. Stein E, Strutt KL, Miller E, Southworth H. Comparison of rosuvastatin verus atorvastatin in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 2003; 92: 1287–93.
16. Schuster H. Rosuvastatin – a highly effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: review of clinical trial at 10–40 mg disease in dyslipidemic patients. Cardiology 2003; 99: 126–39.
17. Schuster H. The GALAXY Program: an update on studies intestigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Rev Cardiovasc Ther 2007; 5: 177–92.
18. Copin C, Davidson R, McTaggiart F et al. Rosuvastatin reduces MMP-9 and MMP-7 secretion by human monocyte-derived macrophages. Int J Clin Pract 2002; 124 (Suppl.): 7.
19. Napoli PD, Taccardi AA, Grilli A et al. Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts. Cardiovasc Res 2005; 66: 462–71.
20. Hunninghake DB, Stein EA, Bays HE et al. Rosuvastatin improves the atherogenic and artheroprotective lipid profile in patients with hypertriglyceridaemia. Coron Artery Dis 2004; 15: 115–23.
21. Blasetto JW, Stein EA, Brown WV et al. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups Am J Cardiol 2003; 91 (Suppl.): 3C–10C.
22. Ballantyne CM, Stein EA, Paoletti R et al. Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome. Am J Cardiol 2003; 91 (Suppl.): 25C–8C.
23. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleotropic effects of statins: benefit beyond cholesterol reduction? JACC 2005; 46 (10): 1855–62.
24. Cannon CP, Braunwald E, McCabe CH et al. Pravastatin or atorvastatin evaluation and infection therapy-thombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl Med 2004; 350: 1495–504.
25. Nissen SE, Tuzcu EM, Schoenhagen P et al. REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized control trial. JAMA 2004; 291: 1071–80.
26. Ridker P et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195–207.
27. Betteridge D, Gibson M. Effect of rosuvastatin and atorvastatin on LDL-C and CRP levels in patients with type 2 diabetes: results of the ANDROMEDA study. Atherosclerosis 2004; 5 (Suppl.): 107 Abs M464.
28. Nissen SE, Stephen JN., Sipahi I et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA 2006; 295: 1556–65.
29. Nissen SE, Tuzcu EM, Beown BG et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291: 1071–80.
30. Buchwald H, Matts JP, Fitch LL. The Program on the Surgical Control of the Hyperlipidemias (POSCH) Group. «Changes in sequential coronary arteriograms and subsequent coronary events». JAMA 1992; 268: 1429–33.
31. Crouse III JR, Raichlen JS, Evans GW et al. Effects of Rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical аtherosclerosis. The METEOR trial. JAMA 2007; 297: 1344–53.